{"id":97707,"date":"2025-09-08T08:37:53","date_gmt":"2025-09-08T06:37:53","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=97707"},"modified":"2026-03-20T11:16:38","modified_gmt":"2026-03-20T10:16:38","slug":"fyb206-pembrolizumab-biosimilar-candidate","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/","title":{"rendered":"FYB206 Pembrolizumab Biosimilar Candidate"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221;]FYB206[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;468775&#8243; text_color_type=&#8221;uncode-palette&#8221;]Pembrolizumab Biosimilar Candidate[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;142465&#8243;]FYB206 is a biosimilar candidate for Keytruda<strong><sup>\u00ae<\/sup><\/strong> (pembrolizumab). Keytruda\u00ae* is used in cancer immunotherapy for the treatment of various tumor diseases.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;2&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;2&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; style=&#8221;dark&#8221; back_color=&#8221;color-729909&#8243; overlay_alpha=&#8221;50&#8243; shadow=&#8221;xl&#8221; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;1208&#8243;][vc_custom_heading text_color=&#8221;color-xsdn&#8221; heading_semantic=&#8221;p&#8221; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; uncode_shortcode_id=&#8221;104757&#8243; text_color_type=&#8221;uncode-palette&#8221;]Development Progress[\/vc_custom_heading][vc_empty_space empty_h=&#8221;1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243;][vc_progress_bar values=&#8221;%5B%7B%22label%22%3A%22Technical%20Development%22%2C%22value%22%3A%22100%22%2C%22bar_color_type%22%3A%22uncode-palette%22%2C%22bar_color%22%3A%22color-167183%22%2C%22bar_color_solid%22%3A%22%23ff0000%22%2C%22back_color_type%22%3A%22uncode-palette%22%2C%22back_color_solid%22%3A%22%23ff0000%22%7D%5D&#8221;][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243;][vc_progress_bar values=&#8221;%5B%7B%22label%22%3A%22Manufacturing%22%2C%22value%22%3A%22100%22%2C%22bar_color_type%22%3A%22uncode-palette%22%2C%22bar_color%22%3A%22color-167183%22%2C%22bar_color_solid%22%3A%22%23ff0000%22%2C%22back_color_type%22%3A%22uncode-palette%22%2C%22back_color_solid%22%3A%22%23ff0000%22%7D%5D&#8221;][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243;][vc_progress_bar values=&#8221;%5B%7B%22label%22%3A%22Clinical%20Development%22%2C%22value%22%3A%2290%22%2C%22bar_color_type%22%3A%22uncode-palette%22%2C%22bar_color%22%3A%22color-167183%22%2C%22bar_color_solid%22%3A%22%23ff0000%22%2C%22back_color_type%22%3A%22uncode-palette%22%2C%22back_color_solid%22%3A%22%23ff0000%22%7D%5D&#8221;][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243;][vc_progress_bar values=&#8221;%5B%7B%22label%22%3A%22Approval%20Process%22%2C%22value%22%3A%220%22%2C%22bar_color_type%22%3A%22uncode-palette%22%2C%22bar_color%22%3A%22color-167183%22%2C%22bar_color_solid%22%3A%22%23ff0000%22%2C%22back_color_type%22%3A%22uncode-palette%22%2C%22back_color_solid%22%3A%22%23ff0000%22%7D%5D&#8221;][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;109864&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;2&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;147152&#8243; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;144524&#8243;]<strong>Indication Area<br \/>\n<\/strong>Immuno-Oncology[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;649979&#8243;]<strong>Active Ingredient Group<br \/>\n<\/strong>PD1 Inhibitor[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;130748&#8243;]<strong>Indications of the Reference Drug<br \/>\n<\/strong>Advanced melanoma, Non-small cell bronchial carcinoma, Hodgkin\u2019s lymphoma, Urothelial carcinomas, Tumors in the head and neck area, other tumor diseases*[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;181127&#8243;]<strong>Business Modell:<br \/>\n<\/strong>100 % Formycon Project[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;535638&#8243;]<strong>Market Launch<br \/>\n<\/strong>in the United States and the EU after loss of exclusivity of the reference drug[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;192120&#8243;]<strong>Pembrolizumab Market<\/strong><br \/>\nits broad range of indications in oncology and sales of $31.7 billion in 2025, Keytruda\u00ae is one of the world\u2019s best-selling drugs.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;205982&#8243; el_width=&#8221;100%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;176429&#8243;]<b>Commercialization partners:<\/b>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;106604&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-99204 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/02\/Zydus_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Region:<\/strong> U.S. \/ Canada[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;196079&#8243;]<strong><img decoding=\"async\" class=\"alignnone size-full wp-image-97801\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/MSPharma_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><\/strong><br \/>\n<strong>Region:<\/strong> MENA<\/p>\n<p><strong>\u00a0<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;187503&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97798 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Lotus_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Region:<\/strong> APAC[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183068&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;149492&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;180139&#8243;]<\/p>\n<div style=\"text-align: right;\">* The specific indication groups approved are listed in the product information<br \/>\nprovided by the EMA or FDA.<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;118803&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97722&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;163486&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;202553&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_empty_space empty_h=&#8221;4&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;226595&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB206 Biosimilar Development[\/vc_custom_heading][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;447782&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;96109&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;209157&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;801105&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_size=&#8221;h4&#8243; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;141761&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB206 Biosimilar Development[\/vc_custom_heading][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;185374&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;102763&#8243; column_width_pixel=&#8221;800&#8243;][vc_empty_space empty_h=&#8221;3&#8243; mobile_visibility=&#8221;yes&#8221;][vc_accordion typography=&#8221;yes&#8221; gutter_simple=&#8221;0&#8243; uncode_shortcode_id=&#8221;605931&#8243; el_id=&#8221;devdetails&#8221; el_class=&#8221;devdetails&#8221; active_tab=&#8221;0&#8243;][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Pembrolizumab Mode of Action&#8221; tab_id=&#8221;1730916296154-2-10174469904047817460256770061762330270387&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183589&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;The active ingredient pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is used to treat a variety of tumors. Pembrolizumab binds to the PD-1 receptor and specifically blocks the interaction between PD-1 and its ligand PD-L1. This supports the immune system in activating the body&#8217;s own cellular anti-tumor immune response and &#8211; for example &#8211; killing melanoma cells.&#8221; uncode_shortcode_id=&#8221;154410&#8243; heading_custom_size=&#8221;24px&#8221;]How does Pembrolizumab work?[\/vc_custom_heading][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;132757&#8243;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/overview\/keytruda-epar-medicine-overview_en.pdf\" target=\"_blank\" rel=\"noopener\">Further Information<\/a><\/p>\n<p>[\/vc_column_text][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Development Milestones&#8221; tab_id=&#8221;1730790947-1-35174469904047817460256770061762330270387&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;188630&#8243;][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;121543&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2026<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Dahlia PK study demonstrates pharmacokinetic equivalence with the reference drug Keytruda\u00ae<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-positive-clinical-data-for-keytruda-biosimilar-candidate-fyb206-pembrolizumab\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;179284&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2026<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Lotus Pharmaceutical becomes commercialization partner for major parts of the APAC region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/lotus-pharmaceutical-becomes-commercialization-partner-for-formycons-keytruda-biosimilar-candidate-fyb206-across-major-parts-of-the-asia-pacific-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;541379&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Zydus becomes commercialization partner for the U.S. and Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-zydus-partner-for-exclusive-licensing-and-supply-agreement-of-fyb206-a-biosimilar-to-keytruda-pembrolizumab-in-the-u-s-and-canada\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;453778&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">MS Pharma becomes commercialization partner for the MENA region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-ms-pharma-sign-exclusive-commercialization-partnership-for-keytruda-biosimilar-candidate-fyb206-for-the-mena-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;630645&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">July 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon\u00a0successfully completes patient enrollment for the clinical development<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-successfully-completes-patient-enrollment-for-the-clinical-development-of-its-keytruda-biosimilar-candidate-fyb206\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;576879&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Based on the stringent study design and comprehensive analytical data demonstrating high structural and functional comparability with the reference drug, Formycon has agreed with the FDA on a streamlined clinical development program that does not require a Phase III study.<\/span>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;367131&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon publishes results of analytical similarity study of biosimilar candidate FYB206 and Keytruda\u00ae in peer-reviewed journal Drugs in R&amp;D<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and-keytruda-in-peer-reviewed-journal-drugs-in-rd\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;139353&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of Clinical Development<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-starts-clinical-development-program-for-fyb206-a-biosimilar-candidate-for-immuno-oncology-blockbuster-drug-keytruda\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;508774&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon discloses the reference drug for biosimilar candidate FYB206<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-publishes-details-of-a-previously-undisclosed-pipeline-project-fyb206-is-a-biosimilar-candidate-for-keytruda-pembrolizumab\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Scientific Publications on FYB206&#8243; tab_id=&#8221;1730790947-2-50174469904047817460256770061762330270387&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;693360&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;Analytical study on the comparability of the biosimilar candidate FYB206 with Keytruda\u00ae&#8221; uncode_shortcode_id=&#8221;119768&#8243; heading_custom_size=&#8221;24px&#8221;]Preclinical data[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][vc_gallery el_id=&#8221;gallery-130684&#8243; type=&#8221;carousel&#8221; medias=&#8221;97755,97765,97767&#8243; carousel_lg=&#8221;3&#8243; carousel_md=&#8221;2&#8243; carousel_sm=&#8221;1&#8243; gutter_size=&#8221;3&#8243; media_items=&#8221;media|custom_link|original,description,icon,caption&#8221; carousel_interval=&#8221;3000&#8243; carousel_navspeed=&#8221;400&#8243; carousel_loop=&#8221;yes&#8221; stage_padding=&#8221;0&#8243; single_text=&#8221;under&#8221; single_overlay_opacity=&#8221;50&#8243; single_padding=&#8221;2&#8243; uncode_shortcode_id=&#8221;142347&#8243; single_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Funternehmen%2Fkontakt%2F|title:Kontakt&#8221; items=&#8221;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&#8221;][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][\/vc_accordion][vc_empty_space empty_h=&#8221;4&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;191448&#8243;]Keytruda\u00ae is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co, Inc, Rahway, NJ\/USA.[\/vc_column_text][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":89494,"parent":78082,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-97707","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FYB206 Pembrolizumab Biosimilar Candidate - Formycon AG<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FYB206 Pembrolizumab Biosimilar Candidate - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T10:16:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3840\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/\",\"url\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/\",\"name\":\"FYB206 Pembrolizumab Biosimilar Candidate - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg\",\"datePublished\":\"2025-09-08T06:37:53+00:00\",\"dateModified\":\"2026-03-20T10:16:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg\",\"width\":3840,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars\",\"item\":\"https:\/\/www.formycon.com\/en\/biosimilars\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FYB206 Pembrolizumab Biosimilar Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FYB206 Pembrolizumab Biosimilar Candidate - Formycon AG","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"en_US","og_type":"article","og_title":"FYB206 Pembrolizumab Biosimilar Candidate - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/","og_site_name":"Formycon AG","article_modified_time":"2026-03-20T10:16:38+00:00","og_image":[{"width":3840,"height":1440,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/","url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/","name":"FYB206 Pembrolizumab Biosimilar Candidate - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg","datePublished":"2025-09-08T06:37:53+00:00","dateModified":"2026-03-20T10:16:38+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2022\/09\/ThoraxRoentgen.jpg","width":3840,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb206-pembrolizumab-biosimilar-candidate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosimilars","item":"https:\/\/www.formycon.com\/en\/biosimilars\/"},{"@type":"ListItem","position":3,"name":"FYB206 Pembrolizumab Biosimilar Candidate"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-15 13:27:29","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=97707"}],"version-history":[{"count":7,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97707\/revisions"}],"predecessor-version":[{"id":99373,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97707\/revisions\/99373"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/89494"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=97707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}